• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. UPDATE: Google, Amazon earnings on tap after hours

    UPDATE: Google, Amazon earnings on tap after hours

  2. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  3. The Fallon Company Continues Fan Pier Momentum As It Celebrates Topping Off of 100 Northern Avenue

    The Fallon Company Continues Fan Pier Momentum As It Celebrates Topping Off of 100 Northern Avenue

  4. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  5. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  6. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

  7. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  8. Best Positioned for Health-Care Reform

    This screen finds companies ready to take advantage when majorĀ provisions of law take effect in 2014.

  9. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  10. Managing Expectations, Part II

    On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.